Experienced in Metastatic Pleural Tumor

Dr. Sylvia M. Lee

Hematology Oncology | Oncology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Experienced in Metastatic Pleural Tumor
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sylvia Lee is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Metastatic Pleural Tumor. Her top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Endoscopy. Dr. Lee is currently accepting new patients.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Korean
Mandarin
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug, Biological
Study Drugs: CART-TnMUC1, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Drugs: KITE-439, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug, Other, Biological
Study Drugs: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Therapeutic Tumor Infiltrating Lymphocytes
Study Phase: Phase 2
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Enrollment Status: Terminated
Publish Date: September 13, 2021
Intervention Type: Drug, Biological, Other, Procedure
Study Drugs: Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

43 Total Publications

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Similar Doctors
Distinguished in Metastatic Pleural Tumor
Dr. Bernardo H. Goulart
Oncology
Distinguished in Metastatic Pleural Tumor
Dr. Bernardo H. Goulart
Oncology
825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-667-2778
Languages Spoken:
English, Portuguese
See accepted insurances
Accepting New Patients

Bernardo Goulart is an Oncologist in Seattle, Washington. Dr. Goulart is rated as a Distinguished provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Metastatic Pleural Tumor. Dr. Goulart is currently accepting new patients.

Advanced in Metastatic Pleural Tumor
Dr. Rafael Santana
Oncology
Advanced in Metastatic Pleural Tumor
Dr. Rafael Santana
Oncology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
 (2.8 miles away)
206-386-3751
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rafael Santana is an Oncologist in Seattle, Washington. Dr. Santana is rated as a Distinguished provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Advanced in Metastatic Pleural Tumor
Dr. Joseph G. Rosales
Hematology Oncology | Hematology | Oncology
Advanced in Metastatic Pleural Tumor
Dr. Joseph G. Rosales
Hematology Oncology | Hematology | Oncology

Virginia Mason Medical Center

33501 1st Way S, 
Federal Way, WA 
 (24.1 miles away)
253-838-2400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Rosales is a Hematologist Oncology specialist and a Hematologist in Federal Way, Washington. Dr. Rosales is rated as a Distinguished provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Large-Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Rosales is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile